X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16471) 16471
Dissertation (209) 209
Book Chapter (144) 144
Publication (25) 25
Conference Proceeding (17) 17
Government Document (15) 15
Book / eBook (5) 5
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pi3k (7336) 7336
humans (6921) 6921
animals (5166) 5166
apoptosis (4662) 4662
oncology (4074) 4074
phosphatidylinositol 3-kinases - metabolism (3970) 3970
akt (3523) 3523
signal transduction (3370) 3370
proto-oncogene proteins c-akt - metabolism (3361) 3361
cancer (3229) 3229
expression (3070) 3070
activation (3065) 3065
cell biology (2984) 2984
mice (2789) 2789
pi3k/akt (2715) 2715
biochemistry & molecular biology (2686) 2686
cell line, tumor (2582) 2582
phosphorylation (2422) 2422
female (2404) 2404
signal transduction - drug effects (2348) 2348
male (2183) 2183
kinases (2078) 2078
proteins (2045) 2045
pharmacology & pharmacy (1920) 1920
1-phosphatidylinositol 3-kinase (1746) 1746
proliferation (1676) 1676
growth (1577) 1577
akt protein (1548) 1548
pathway (1492) 1492
phosphatidylinositol 3-kinases - antagonists & inhibitors (1463) 1463
apoptosis - drug effects (1460) 1460
inhibition (1431) 1431
cell proliferation (1417) 1417
metastasis (1346) 1346
mtor (1344) 1344
pi3k/akt pathway (1343) 1343
analysis (1312) 1312
rats (1252) 1252
medicine, research & experimental (1236) 1236
cells (1208) 1208
cell proliferation - drug effects (1204) 1204
gene expression (1183) 1183
tumors (1139) 1139
phosphatidylinositol 3-kinases - genetics (1124) 1124
pten (1120) 1120
research (1075) 1075
breast cancer (1062) 1062
cell cycle (1024) 1024
mutation (1023) 1023
phosphatidylinositol 3-kinase (991) 991
tor serine-threonine kinases - metabolism (986) 986
antineoplastic agents - pharmacology (963) 963
survival (961) 961
phosphoinositide 3-kinase (958) 958
cell growth (951) 951
health aspects (920) 920
inflammation (920) 920
autophagy (914) 914
kinase (894) 894
oxidative stress (891) 891
signaling pathway (884) 884
cells, cultured (856) 856
migration (837) 837
genetic aspects (830) 830
middle aged (826) 826
chemotherapy (822) 822
in-vitro (817) 817
care and treatment (809) 809
invasion (793) 793
resistance (784) 784
neurosciences (758) 758
protein kinase inhibitors - pharmacology (756) 756
breast-cancer (749) 749
nf-kappa-b (737) 737
signal transduction - physiology (731) 731
proto-oncogene proteins c-akt - genetics (723) 723
cell line (714) 714
pi3k/akt/mtor pathway (707) 707
development and progression (704) 704
chemistry, medicinal (701) 701
cell survival - drug effects (687) 687
morpholines - pharmacology (675) 675
enzyme inhibitors - pharmacology (670) 670
protein (669) 669
blotting, western (661) 661
immunology (650) 650
adult (646) 646
down-regulation (641) 641
carcinoma (639) 639
aged (632) 632
cancer therapies (632) 632
proto-oncogene proteins c-akt - antagonists & inhibitors (621) 621
prognosis (620) 620
angiogenesis (612) 612
signaling (611) 611
therapy (601) 601
mapk (598) 598
up-regulation (589) 589
dose-response relationship, drug (584) 584
rapamycin (582) 582
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16619) 16619
Chinese (106) 106
Japanese (68) 68
French (66) 66
Korean (52) 52
German (23) 23
Portuguese (14) 14
Polish (9) 9
Russian (7) 7
Spanish (5) 5
Turkish (5) 5
Czech (4) 4
Bosnian (1) 1
Hungarian (1) 1
Indonesian (1) 1
Lithuanian (1) 1
Persian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical journal, ISSN 1470-8728, 2011, Volume 438, Issue 1, pp. 53 - 62
Genetic alterations in PI3K (phosphoinositide 3-kinase) signalling are common in cancer and include deletions in PTEN (phosphatase and tensin homologue deleted... 
Phosphoinositide 4-kinase (PI4K) | Pan-phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235; phosphoinositide 3-kinase α (PI3Kα) | PIK3CA | p110α E545k mutation | PIK3CA H1047R mutation | PIK3CA MUTATIONS | BIOCHEMISTRY & MOLECULAR BIOLOGY | p110 alpha E545K mutation | PTEN | phosphoinositide 4-kinase (PI4K) | PI3K-ALPHA | PROLIFERATION | CANCER | pan-phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235 | INSULIN | P110-BETA | phosphoinositide 3-kinase alpha (PI3K alpha) | ROLES | INHIBITORS | IA PI3K ISOFORMS | Class Ia Phosphatidylinositol 3-Kinase - metabolism | Humans | Neoplasms, Experimental - prevention & control | Enzyme Inhibitors - therapeutic use | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Mice, Knockout | Neoplasms, Experimental - pathology | Tissue Distribution | Animals | Enzyme Inhibitors - pharmacokinetics | Signal Transduction - drug effects | Protein Isoforms | Mice | Neoplasms, Experimental - metabolism | Tumor Cells, Cultured | Homeodomain Proteins - physiology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | PI3K, phosphoinositide 3-kinase | BID, twice daily dosing | p110α E545K mutation | mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235; phosphoinositide 3-kinase α (PI3Kα) | PTEN, phosphatase and tensin homologue deleted on chromosome 10 | ERK, extracellular-signal-regulated kinase | PKB, protein kinase B | pan-phosphoinositide 3kinase (PI3K) | PI4K, phosphoinositide 4-kinase | QD, once daily dosing | mTOR, mammalian target of rapamycin | TGI, tumour growth inhibition
Journal Article
Biomolecules (Basel, Switzerland), ISSN 2218-273X, 2019, Volume 9, Issue 3, p. 82
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 2009, Volume 9, Issue 8, pp. 738 - 753
In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3K delta) and gamma (PI3K gamma) as therapeutic... 
Allergy | Inflammation | PI3K | Rheumatoid arthritis | Asthma | COPD | RHEUMATOID-ARTHRITIS | CHEMISTRY, MEDICINAL | MYOCARDIAL-INFARCTION | PHOSPHATIDYLINOSITOL 3-KINASE | allergy | SELECTIVE KINASE INHIBITORS | asthma | ISOFORM | rheumatoid arthritis | WORTMANNIN | LIPID KINASE | POTENT | inflammation | EMBRYONIC LETHALITY | PI3K-GAMMA INHIBITION
Journal Article
Biomolecules (Basel, Switzerland), ISSN 2218-273X, 2019, Volume 9, Issue 3, p. 104
Journal Article
Leukemia & lymphoma, ISSN 1029-2403, 2015, Volume 56, Issue 10, pp. 2779 - 2786
Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood... 
phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor | transaminitis | colitis | pneumonitis | Idelalisib | diarrhea | Idelalisib, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor | phosphatidylinositol 3-kinase delta (PI3K) inhibitor | CAL-101 | DELTA | P110-DELTA | PI3K | ONCOLOGY | INHIBITOR | HEMATOLOGY | SUBUNIT | Index Medicus | Reviews | Review
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 05/2016, Volume 16, Issue 13, pp. 1413 - 1426
The PI3K signaling cascade is the key moderator of cell proliferation, survival, motility, and apoptosis. Class I PI3K proteins are well characterized and... 
LY294002 | NVP-BEZ235 | BRAF | Selectivity | PI3Kγ | GDC-0941 | EGFR | P100α | PI3K/AKT | MEK | Class I PI3Ks | mTOR | Drug design | GSK2118436 | KRAS | Mutation | Anticancer | PI3K gamma | PI3K/MTOR | PI3K-BETA INHIBITORS | ISOFORM SELECTIVITY | DISCOVERY | BIOLOGICAL EVALUATION | AMIDE DERIVATIVES | DUAL INHIBITORS | CHEMISTRY, MEDICINAL | SERIES | POTENT | SELECTIVE INHIBITORS | p100 alpha
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2015, Volume 21, Issue 43, pp. 12261 - 12273
Frequent activation of phosphatidylinositol-3 kinases(PI3K)/Akt/m TOR signaling pathway in gastric cancer(GC) is gaining immense popularity with identification... 
Epidemiology;Gastric | pathwa | cancer;PI3K/Akt | m | TOR | Targeted therapy | Epidemiology | Gastric cancer | Predictive biomarkers | PI3K/AKT/ MTOR pathway | CANCER-CELLS | MAMMALIAN TARGET | ADVANCED SOLID TUMORS | CELL-CYCLE PROGRESSION | ANTITUMOR-ACTIVITY | PI3K/Akt/mTOR pathway | AKT/PROTEIN KINASE-B | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | PHOSPHOINOSITIDE 3-KINASES | GASTROENTEROLOGY & HEPATOLOGY | NF-KAPPA-B | PHASE-I | TOR Serine-Threonine Kinases - metabolism | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Drug Discovery - methods | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Proto-Oncogene Proteins c-akt - genetics | TOR Serine-Threonine Kinases - antagonists & inhibitors | Carcinoma - enzymology | Biomarkers, Tumor - metabolism | Biomarkers, Tumor - antagonists & inhibitors | Carcinoma - pathology | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Precision Medicine | Carcinoma - drug therapy | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Treatment Outcome | Stomach Neoplasms - drug therapy | Animals | Phosphatidylinositol 3-Kinase - genetics | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Carcinoma - genetics | Biomarkers, Tumor - genetics | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | PI3K | mTOR pathway | Akt | Topic Highlight
Journal Article
ACS Medicinal Chemistry Letters, ISSN 1948-5875, 10/2016, Volume 7, Issue 10, pp. 908 - 912
Dual inhibition of PI3K-δ and PI3K-γ is an established therapeutic strategy for treatment of hematological malignancies. Reported molecules targeting PI3K-δ/γ... 
PI3K-δ | kinase inhibitor | phosphatidylinositol-4,5-bisphosphate 3-kinase-delta | p110-γ | PI3K-γ | p110-δ | p110-delta | PI3K-gamma | POTENT | CHEMISTRY, MEDICINAL | MODELS | KINASE | p110-gamma | PI3K-GAMMA INHIBITION | PI3K-delta
Journal Article
Journal Article